OSR Health Announces Shareholder Loyalty Program to Reward Conviction Holders With Additional Shares

June 25, 2026 8:32 AM

OSR Health, Inc. (NASDAQ:OSRH) today announced a Shareholder Loyalty Program designed to reward the investors who hold OSRH stock over the long term. Under the program, the Company plans to distribute non-transferable Contingent Value Rights ("CVRs") to all shareholders of record tentatively as of July 31, 2026. One CVR for every share owned. The Board of Directors has authorized management to proceed with implementation, subject to receipt of a...

Read more

DiscGenics Appoints Healthcare Entrepreneur and Medtech Executive Chad Falciani to Board of Directors

June 25, 2026 7:00 AM

DiscGenics, Inc., a privately held, late-stage clinical biopharmaceutical company developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced the appointment of Chad Falciani to its Board of Directors.Mr. Falciani is a proven healthcare entrepreneur, investor, and business leader and is the Founder and Chairman of Curiteva, a high-growth medical...

Read more

eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery

June 24, 2026 4:10 PM

eXoZymes Inc. (NASDAQ:EXOZ) - a pioneer of AI-enhanced enzymes that enable scalable manufacturing of nutraceuticals and novel pharmaceuticals - today announced that it has received a Notice of Award from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) for a Phase IIB Small Business Innovation Research (SBIR) grant totaling $2,028,518.The NIH funded work is expected to begin July 1, 2026, and...

Read more

Thalia Therapeutics PLC Announces Acquisition and £2.75 Million Fundraise

June 24, 2026 2:15 AM

Thalia Therapeutics plc (AIM:THAT), a biotechnology company developing innovative RNA-based therapeutics and delivery technologies in oncology and cardiovascular disease is pleased to announce the acquisition, conditional upon shareholder approval, of Sanmirna Therapeutics, Inc. ("Sanmirna"), a US Corporation which holds an exclusive licence for the intellectual property and know-how around miRisten an anti-microRNA-126 for the treatment of...

Read more

IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow

June 23, 2026 8:30 AM

IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease and AI-enabled healthcare technologies, today announced the beta version of its proprietary Agentic Harmonization Assistant ("AHA"), an enterprise software platform designed to accelerate the harmonization of fragmented Alzheimer's and aging-related datasets. The announcement comes as IGC...

Read more

Deeply Cultivating Brain Disease Sector, Cloud-Clone Wuhan Forges New Edges in CRO Services

June 22, 2026 10:00 AM

World Parkinson's Day, observed on April 11 annually, continuously raises public awareness of the health and public health burdens brought by Parkinson's disease and other brain disorders. At present, brain diseases such as neurodegenerative illnesses, stroke and traumatic brain injury have emerged as critical global public health challenges. Constrained by complicated pathogenic mechanisms, numerous drug targets and the special physiological...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

June 22, 2026 9:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | June 22, 2026 at 16:00:00 EESTStandard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer:FARON PHARMACEUTICALS OY 2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An...

Read more

OSR Holdings Is Now OSR Health - A New Name That Says Exactly What We Do

June 22, 2026 9:06 AM

OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has officially changed its corporate name to OSR Health, Inc., a fresh identity that more directly reflects the Company's mission. The change became effective on June 11, 2026 upon the filing of a Certificate of Amendment with the Delaware Secretary of State.The rebrand is a clearer articulation of the Company's identity as a global health innovation platform operating across...

Read more

enVVeno Medical to Present in the Webull Corporate Connect Webinar Series

June 22, 2026 9:00 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company setting new standards of care for the treatment of deep venous disease, today announced that it will present in the Webull Corporate Connect Webinar Series being held virtually June 24-25, 2026. As part of the discussion, the Company's CEO, Rob Berman, will provide an overview of enVVeno Medical's mission to transform the treatment of deep venous disease,...

Read more

Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement

June 17, 2026 9:05 PM

Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and...

Read more

Cenna Biosciences Receives FDA Clearance to Begin Phase 1a/1b Clinical Trial of 8M2D, a First-in-Class Peptide Designed to Stop the Production of Amyloid in Alzheimer's Disease

June 17, 2026 6:25 PM

The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of Cenna Biosciences (Cenna) to begin a Phase 1a/1b clinical trial of 8M2D, a first-in-class peptide for the treatment of Alzheimer's disease (AD). 8M2D is designed to address the root cause of AD by inhibiting the production of β-amyloid (Aβ), rather than clearing it after it has already accumulated in the brain. "FDA clearance of our IND is a...

Read more

LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide

June 17, 2026 6:00 PM

LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company")is pleased to announce the successful final completion of its comparative mouse study (the "Study") evaluating protamine-enhanced skin permeation delivery of GLP/GIP-based therapies1. The Study has now been completed for both semaglutide and tirzepatide, with closely aligned and reproducible results observed across the two molecules.As previously...

Read more

eXoZymes Inc. Announces Closing of $6 Million Public Offering

June 17, 2026 4:10 PM

eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines, today announced the closing of its previously announced underwritten public offering of common stock and warrants.The offering consisted of 330,575 units, including 34,440 units sold in partial exercise of over-allotment option, each unit consisting of two shares of common...

Read more

Faron Pharmaceuticals LTD: Holding(s) in Company

June 17, 2026 9:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 16:30:00 EESTTR-1: Standard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd1b. Please...

Read more

Commonwealth of Massachusetts Honors Longwood Fund and Christoph Westphal with Governor's Citation

June 17, 2026 7:00 AM

Longwood Fund, a venture capital firm creating and investing in science-based companies that develop important treatments to help patients, today announced that Massachusetts Governor Maura Healey honored Longwood Fund and Christoph Westphal, MD, PhD, General Partner of Longwood Fund, with the presentation of the Governor's Citation, recognizing Dr. Westphal's career as a physician-scientist, entrepreneur, investor, and CEO, advancing...

Read more

Year-End Report 2025-2026

June 17, 2026 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Strong growth provides the platform for the next commercial phaseBiovica ended the fiscal year with strong growth in both the fourth quarter and for the full fiscal year, while making important progress in expanding the clinical evidence base, the Pharma Services area, and adoption of DiviTum TKa in the USA. Biovica is embarking on the next commercial phase with a sharper focus,...

Read more

Faron Pharmaceuticals LTD: Holding(S) In Company

June 17, 2026 2:15 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | June 17, 2026 at 09:00:00 EESTStandard form for notification of major holdingsNOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA) 1. Identity of the issuer:FARON PHARMACEUTICALS OY2. Reason for the notification (please tick the appropriate box or boxes):☐ An acquisition or disposal of shares or voting rights☒ An...

Read more

Landmark Liver Fibrosis Research Published in Cell, Cloud-Clone Aids ROCK2-Targeted Drug TDI01 Development

June 16, 2026 3:00 PM

In April 2026, a groundbreaking study-Selective targeting of endothelial and perivascular angiocrine ROCK2 treats liver fibrosis-was published online in the prestigious international journal Cell. This research reveals for the first time that selective upregulation of ROCK2 in liver endothelial cells and perivascular hepatic stellate cells serves as a core mechanism driving the progression of liver fibrosis. The study has successfully led to the...

Read more

Everything Leaves A Trace: eDNA Technology Empowers Environmental Protection in China

June 16, 2026 4:33 AM

Since 2021, the China Zhi Gong Party has been carrying out a Yangtze River eco-environmental protection project in partnership with east China's Anhui Province. Faced with the complex challenge of river basin management, the party's central committee has leveraged its intellectual resources, bringing together a think tank of leading experts to launch a five-year "science and technology empowerment" initiative across the Jianghuai region, the...

Read more

Lifeloc Completes SpinDetect(TM) Disk Production Tooling, Commissions Cleanroom, and Outlines Staged Commercial Rollout

June 15, 2026 4:18 PM

Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, today provided an update on its SpinDetect™ Centrifugal Drug Analyzer program and its core breath alcohol business.Lifeloc has completed the production mold for the SpinDetect consumable test disks and produced first-article disks, which have undergone initial testing. Minor mold modifications identified...

Read more